成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Apoptosis Anti-infection
  2. Apoptosis Bacterial
  3. Carnosic acid

Carnosic acid 是一種具有口服活性的脂質(zhì)吸收抑制劑。Carnosic acid 能夠抑制氧化應(yīng)激和炎癥,抑制細(xì)胞增殖,并擁有抗菌活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Carnosic acid Chemical Structure

Carnosic acid Chemical Structure

CAS No. : 3650-09-7

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機(jī)構(gòu)(單位)一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
5 mg ¥326
In-stock
10 mg ¥489
In-stock
25 mg ¥1000
In-stock
50 mg ¥1600
In-stock
100 mg ¥2240
In-stock
500 mg ¥5613
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Carnosic acid:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Carnosic acid is an orally active lipid absorption inhibitor. Carnosic acid has demonstrated inhibition of oxidative stress and inflammation, suppression of cell proliferation, and antibacterial activity.

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
5 μM
Compound: 8
Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis
Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis
10.1039/C5MD00278H
AGS IC50
89.8 μM
Compound: 1
Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay
[PMID: 20359186]
Hepatocyte EC50
94.8 μM
Compound: CA, Carnosic acid
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay
[PMID: 22531045]
Hepatocyte EC50
95.7 μM
Compound: CA, Carnosic acid
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay
[PMID: 22531045]
HepG2 IC50
41.3 μM
Compound: 1
Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay
[PMID: 20359186]
MIA PaCa-2 EC50
5.5 μM
Compound: CA
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
[PMID: 31725297]
MRC5 IC50
21.8 μM
Compound: 1
Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay
[PMID: 20359186]
PANC-1 EC50
150 μM
Compound: CA
Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
[PMID: 31725297]
體外研究
(In Vitro)

Carnosic acid 是一種酚類(lèi)二萜,富含于唇形科植物的葉子中,在迷迭香和鼠尾草的干燥葉子中含量特別高。Carnosic acid 已證明可抑制氧化應(yīng)激和炎癥、抑制細(xì)胞增殖和抗菌活性。據(jù)廣泛報(bào)道,Carnosic acid 在不同類(lèi)型的癌癥中具有處理潛力,主要基于體外實(shí)驗(yàn)。Carnosic acid 還在神經(jīng)退行性疾病的實(shí)驗(yàn)?zāi)P椭酗@示出神經(jīng)保護(hù)作用,主要是通過(guò)激活抗氧化劑 NRF2/ARE 通路[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

332.43

Formula

C20H28O4

CAS 號(hào)
性狀

固體

顏色

White to light yellow

結(jié)構(gòu)分類(lèi)
初始來(lái)源
運(yùn)輸條件

Shipping with dry ice.

儲(chǔ)存方式

-80°C, stored under nitrogen

溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn): 

DMSO 中的溶解度 : 130 mg/mL (391.06 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響,請(qǐng)使用新開(kāi)封的 DMSO)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 3.0082 mL 15.0408 mL 30.0815 mL
5 mM 0.6016 mL 3.0082 mL 6.0163 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
儲(chǔ)備液的保存方式和期限:-80°C, 6 months (stored under nitrogen)。-80°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn):

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液,再依次添加助溶劑:
——為保證實(shí)驗(yàn)結(jié)果的可靠性,澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.52 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.08 mg/mL (6.26 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.08 mg/mL的均勻懸濁液,懸濁液可用于口服和腹腔注射。

    1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息:

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

由于實(shí)驗(yàn)過(guò)程有損耗,建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購(gòu)。 Tween 80,均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度,以下方案僅供參考,如有需要,請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液,加入 μL  μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過(guò)半月以上,請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.15%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液;一旦配成溶液,請(qǐng)分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
儲(chǔ)備液的保存方式和期限:-80°C, 6 months (stored under nitrogen)。-80°C 儲(chǔ)存時(shí),請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.0082 mL 15.0408 mL 30.0815 mL 75.2038 mL
5 mM 0.6016 mL 3.0082 mL 6.0163 mL 15.0408 mL
10 mM 0.3008 mL 1.5041 mL 3.0082 mL 7.5204 mL
15 mM 0.2005 mL 1.0027 mL 2.0054 mL 5.0136 mL
20 mM 0.1504 mL 0.7520 mL 1.5041 mL 3.7602 mL
25 mM 0.1203 mL 0.6016 mL 1.2033 mL 3.0082 mL
30 mM 0.1003 mL 0.5014 mL 1.0027 mL 2.5068 mL
40 mM 0.0752 mL 0.3760 mL 0.7520 mL 1.8801 mL
50 mM 0.0602 mL 0.3008 mL 0.6016 mL 1.5041 mL
60 mM 0.0501 mL 0.2507 mL 0.5014 mL 1.2534 mL
80 mM 0.0376 mL 0.1880 mL 0.3760 mL 0.9400 mL
100 mM 0.0301 mL 0.1504 mL 0.3008 mL 0.7520 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機(jī)構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
Carnosic acid
目錄號(hào):
HY-N0644
需求量: